Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ye Eun Kwak

Gastroenterology Mount Pleasant, WI Medical Doctor

NPI 1205218658 CMS profile 4232481

8400 Washington Ave, Mount Pleasant, WI 53406

Open in the dashboard

General payments

$3,290

36 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ye Eun Kwak of Mount Pleasant, WI is reported in the CMS Open Payments database as having received $3,290 across 36 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $147 1
2024 General $694 5
2023 General $762 5
2022 General $541 9
2021 General $431 10
2019 General $715 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ye Eun Kwak
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Ye Eun Kwak were reported at $147. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Ye Eun Kwak Gastroenterology median Middle half National median
2019 $715 $417 $126–$1,100 $163
2020 $0 $224 $74–$624 $114
2021 $431 $352 $106–$1,054 $132
2022 $541 $448 $129–$1,270 $149
2023 $762 $533 $150–$1,390 $160
2024 $694 $605 $160–$1,606 $164
2025 $147 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $460 4 payments
  2. Nevro Corp. $391 3 payments
  3. Boston Scientific Corporation $374 2 payments
  4. Janssen Biotech, Inc. $304 11 payments
  5. Janssen Scientific Affairs, LLC $298 3 payments
  6. Painteq LLC $237 1 payment
  7. Gilead Sciences, Inc. $233 2 payments
  8. SPR Therapeutics, Inc $229 2 payments
  9. Abbott Laboratories $198 1 payment
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $122 1 payment
  11. Other $444 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,290 36 payments
Products named General payments · program years 2019–2025
  1. STELARA $602 14 payments
  2. Omnia $391 3 payments
  3. RELISTOR $336 3 payments
  4. PAINTEQ $237 1 payment
  5. Vemlidy $233 2 payments
  6. SPRINT PNS System $229 2 payments
  7. PROCLAIM $198 1 payment
  8. Axonics $147 1 payment
  9. PLENVU $124 1 payment
  10. JARDIANCE $122 1 payment
  11. Other $509 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

832

Median for Gastroenterology: 569

Drug cost

$73,785

Median for Gastroenterology: $104,976

Branded share of claims

44%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 49 $29,438
Mounjaro Tirzepatide Brand 18 $18,075
Trulance Plecanatide Brand 12 $10,342
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 67 $3,973
Cholestyramine Cholestyramine (With Sugar) Brand 24 $2,141
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 125 $1,724
Sucralfate Generic 12 $1,277
Ursodiol Generic 13 $1,041
Pantoprazole Sodium Generic 65 $973
Lubiprostone Generic 12 $951

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$36,052

Medicare's payments for the services billed

Medicare patients

181

Average age 71

Services billed

366

107 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 34%
Ischemic heart disease 33%
Chronic kidney disease 33%
COPD 28%
Depression 28%
Atrial fibrillation 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

36 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record